Drug repositioning identifies where existing medicines have value beyond their original indication, creating a more focused starting point for biotech teams in therapeutic discovery. For scientists, its value lies in connecting known drug biology to a new disease context with enough mechanistic confidence to justify further investigation.

One way to support this process is through drug target affinity prediction. In this context, the goal is to estimate whether an existing drug is likely to bind a disease-relevant protein target, and how strong that interaction may be. This helps move from a broad set of possible repositioning candidates toward a more focused list of drug-target hypotheses.

Drug target affinity prediction does not provide a final therapeutic answer. It provides a structured prioritisation layer. When combined with disease biology, target relevance and experimental validation, it can help you identify which existing molecules are worth studying in a new indication.

What is drug repositioning and why is it used in drug discovery?

Drug repositioning is the process of identifying new therapeutic uses for existing drugs, clinical-stage compounds, discontinued assets or drug candidates originally developed for another purpose. It is closely related to drug repurposing, and both terms are often used when teams evaluate whether a known molecule could be relevant in a new disease context.

The principle is that a drug developed for one disease may have biological activity that is useful in another. This relevance can come from its known target, mechanism of action, effect on a pathway or broader cellular response. For biotech and pharma teams, this creates a way to explore new therapeutic opportunities without beginning discovery from a completely novel molecule.

Repositioning can be attractive because some information about the molecule may already exist. Safety, dosing, pharmacokinetics, formulation, manufacturing, exposure, target engagement or clinical history may be better understood than for a new compound. This existing knowledge can help teams assess whether a new indication is worth exploring and may also support portfolio strategy when an asset has stalled in one disease area.

However, prior drug knowledge does not automatically create a new indication. A known safety profile may reduce some uncertainty, but it does not explain where the drug could work next. The target must matter in the right cells, the mechanism must connect to the disease process, and the repositioning hypothesis needs a clear path to validation.

That makes drug repositioning a biological decision-making problem. Existing knowledge, such as safety or pharmacology, can reduce some uncertainty, but teams still need to identify the disease-relevant mechanisms, confirm whether the target is active in the right cellular context and define what evidence is needed before validation begins.

How teams identify repositioning opportunities 

A drug repositioning workflow usually starts with a defined starting point. This may be an existing drug, a target, a pathway, a disease area or a set of molecular signatures. The starting point shapes the question the team needs to answer.

When the starting point is a drug, teams may ask which diseases share relevant biology with that drug’s known effects. When the starting point is a disease, they may ask which existing drugs could influence the targets, pathways or cell states involved in that disease. When the starting point is a target, they may ask which known molecules could engage that target and whether the target is meaningful in the disease context.

Several evidence layers can support this process. Literature, clinical history, pharmacology, omics data, disease models, target expression, pathway activity and computational predictions can all contribute to a repositioning hypothesis. Stronger hypotheses usually combine several of these layers instead of relying on one signal alone.

The goal is to move from a broad set of possible matches to a smaller group of drug-disease hypotheses that can be reviewed scientifically. At this stage, the most useful output is a reasoned shortlist: which existing drugs appear relevant, through which mechanisms, in which disease context, and with what validation path.

Why disease relevance matters 

A drug-target connection does not automatically make a repositioning opportunity strong. A drug may bind a target, influence a pathway or show activity in one biological setting, while the same mechanism may be less relevant in another disease context.

Disease relevance depends on where and how the mechanism appears in the biology of the disease. The target may need to be expressed in a specific cell type. The pathway may need to be active in a disease-relevant cell state. The drug’s effect may need to influence a process that contributes to disease progression, inflammation, fibrosis, immune activity, tissue damage or another relevant mechanism.

This is one reason why modern drug repositioning increasingly depends on disease biology rather than drug lists alone. Existing drugs can be matched to diseases through databases, literature or known targets, but those matches need biological context. Teams need to understand whether the proposed mechanism is active in the right cells, connected to the right disease process and suitable for further validation.

For biotech and pharma teams, disease relevance helps separate broad possibilities from therapeutic opportunities. It gives teams a stronger basis for deciding which repositioning hypotheses deserve experimental follow-up and which are less connected to the disease biology they want to influence.

Why target relevance matters 

Target relevance is another important part of drug repositioning. A drug may have a known target, but the value of that target depends on its role in the new disease context. The same target can have different biological meaning depending on the tissue, cell type, disease stage or surrounding pathway activity.

For repositioning, teams need to understand whether the target is connected to the disease mechanism they want to influence. Is it expressed in the relevant cells? Does it sit near disease-associated pathways? Could changing its activity shift the disease-relevant cell state in a useful direction? These questions help teams assess whether a drug-target hypothesis has enough biological rationale for further investigation.

Target relevance also affects validation planning. If a target appears important in one cell population but not another, the next experiment should reflect that context. If the target is connected to several pathways, teams may need to understand which mechanism is most relevant to the repositioning hypothesis. If the target has safety or selectivity concerns, those questions should be considered early.

In a stronger drug repositioning workflow, target relevance is assessed together with disease relevance, drug biology and available validation options. This gives teams a clearer view of which existing drugs may deserve further study and why.

How TwinCell supports drug repositioning 

TwinCell supports drug repositioning by connecting existing drug biology to disease-relevant cellular mechanisms. Instead of treating repositioning as a simple match between a drug and a disease label, TwinCell helps evaluate whether the drug’s known or predicted effects are connected to the biology of the disease.

This can include several layers of analysis. A drug can be represented through its known targets, mechanism of action or omics-derived response signature. Disease biology can be represented through disease-relevant cell states, pathways and regulatory patterns. TwinCell can then help assess how closely the drug’s biological footprint connects to the disease context.

For repositioning teams, this can support a more structured shortlist of opportunities. A candidate may appear relevant because it engages a target active in the disease, influences a pathway connected to the disease state, or affects cellular mechanisms that may help shift diseased cells toward healthier behaviour.

The output should be treated as a prioritization signal, not as proof of therapeutic effect. TwinCell helps teams identify which drug-disease hypotheses have stronger biological rationale and which hypotheses may deserve experimental validation.

From repositioning hypothesis to validation planning 

A drug repositioning hypothesis becomes useful when it can guide the next scientific decision. After a candidate has been identified, teams need to decide what evidence should be reviewed, what experiments should be designed, and what criteria would make the opportunity worth pursuing.

Validation planning may include several questions. Does the drug engage the relevant target in the right cellular context? Is the pathway active in the disease state? Does the drug influence the disease-relevant cell behaviour that the team wants to modify? Are there safety, selectivity, exposure or formulation questions that need to be addressed before deeper development work?

The validation path should reflect the repositioning rationale. A hypothesis based on immune cell activity may require different models than a hypothesis based on fibrosis, epithelial repair or neuronal signalling. A hypothesis based on target expression may need different evidence than one based on a broader drug response signature.

For biotech and pharma teams, this is where a structured repositioning workflow can reduce unnecessary exploration. By clarifying the drug, target, disease context and expected mechanism, teams can design validation work around the hypotheses with the strongest biological rationale.

From existing drugs to new therapeutic opportunities 

Drug repositioning can help teams find new therapeutic opportunities in existing drugs, but the strength of the opportunity depends on the evidence behind it. Existing safety or clinical history can be useful, but the repositioning case still needs disease relevance, target relevance, biological rationale and a clear validation path.

For biotech and pharma teams, this means drug repositioning should be approached as a structured decision-making process. Which drugs connect to the disease biology? Which mechanisms are active in the right cellular context? Which hypotheses are strong enough to test? Which candidates should be deprioritized before experimental resources are committed?

TwinCell can support this process by helping teams connect existing drugs to disease-relevant cellular mechanisms. By combining drug biology, target relevance and cellular disease context, it can help prioritize repositioning hypotheses that deserve further scientific review.

‍